Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12385780 | 0.84 | SMN1; SMN2 (0.66) | SMN1; SMN2POLBALDH1A1HSD17B10KMT2A | |
| SCHEMBL12384428 | 0.79 | ALDH1A1 (0.40) | POLBALDH1A1HSD11B1KMT2ALMNA | |
| SCHEMBL20346316 | 0.78 | SMN1; SMN2 (0.97) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL12425968 | 0.77 | SMN1; SMN2 (1.00) | SMN1; SMN2POLBALDH1A1HSD17B10HTT | |
| SCHEMBL10224144 | 0.75 | KMT2A (0.55) | POLBALDH1A1HSD11B1KMT2ARECQL | |
| SCHEMBL20464225 | 0.72 | ALDH1A1 (0.44) | SMN1; SMN2POLBALDH1A1HSD11B1KMT2A | |
| SCHEMBL13781662 | 0.72 | MEN1 (0.44) | POLBALDH1A1HSD11B1KMT2ALMNA | |
| SCHEMBL10224222 | 0.72 | POLB (0.56) | SMN1; SMN2POLBALDH1A1KMT2ALMNA | |
| SCHEMBL12904501 | 0.72 | SMN1; SMN2 (0.56) | SMN1; SMN2HTTKMT2ANPC1RAB9A | |
| SCHEMBL12424421 | 0.71 | ALDH1A1 (0.62) | SMN1; SMN2POLBALDH1A1HSD11B1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | SMN1; SMN2 4086/4885POLB 660/4885ALDH1A1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.